Overview

Characteristics of Glargine in Type 2 Diabetics

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will show differing effects on endogenous glucose production, glucose disposal and carbohydrate and lipid flux.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborator:
Sanofi
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc